Valion Bio Inc（VBIO）のニュースとイベントVBIOValion Bio Inc

Valion Bio's New CEO Outlines Three Key Priorities

Valion Bio shared the initial findings and priorities from Dean Zikria's first 30 days as Interim CEO. Mr. Zikria's strategic review has set a focused agenda built on three priorities: Advancing the development of Entolimod and other pipeline assets; Pursuing customer and revenue capabilities for Velocity Bioworks, the Company's wholly owned contract development and manufacturing organization; and Evaluating strategic partnerships, co-investment structures, licensing deals, and/or other transactions for Velocity that could unlock additional value from the CDMO. "Having served on Valion's Board of Directors for more than seven years, I have a deep understanding of the Company's science, assets, and people, and I believe those factors provide a meaningful foundation for future success," said Mr. Zikria. "It is also clear to me there has been a significant and persistent gap between these and how the stock market has seen and valued our Company. My initial review has reinforced the importance of translating our underlying strengths into measurable development progress, commercial traction, and disciplined capital allocation. Our focus is on advancing the opportunities with the greatest potential to create value for shareholders, while remaining pragmatic about how we fund, develop, and commercialize our assets."

Selling Stockholders Plan to Sell Up to 3.95M Shares

This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.95M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

Valion Bio Completes Initial Feasibility Evaluation of LarmorBio's BioScan-NMR

Valion Bio and LarmorBio announced that Velocity Bioworks, Valion's wholly owned biologics contract development and manufacturing organization subsidiary, has successfully completed an initial feasibility evaluation of LarmorBio's BioScan-NMR platform. BioScan-NMR is being developed to create a new class of process analytical technology for biologics manufacturing. The initial feasibility evaluation demonstrated that nuclear magnetic resonance, NMR, measurements have the potential to track microbial growth during a fermentation process. Building on that foundation, LarmorBio is developing a real-time, continuous monitoring platform designed to: Bring biological visibility directly into the manufacturing process, with the potential to detect deviations earlier; Reduce the risk of batch failures; Lower manufacturing costs; Enable more consistent and efficient production